Leerink Partnrs Issues Optimistic Forecast for BOLT Earnings

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) – Investment analysts at Leerink Partnrs boosted their Q1 2025 earnings estimates for Bolt Biotherapeutics in a research note issued on Tuesday, March 25th. Leerink Partnrs analyst D. Graybosch now forecasts that the company will post earnings per share of ($0.34) for the quarter, up from their prior estimate of ($0.41). The consensus estimate for Bolt Biotherapeutics’ current full-year earnings is ($1.61) per share. Leerink Partnrs also issued estimates for Bolt Biotherapeutics’ Q2 2025 earnings at ($0.34) EPS, Q3 2025 earnings at ($0.35) EPS, Q4 2025 earnings at ($0.35) EPS, FY2025 earnings at ($1.38) EPS, FY2026 earnings at ($0.83) EPS, FY2027 earnings at ($0.42) EPS, FY2028 earnings at ($0.30) EPS and FY2029 earnings at ($0.23) EPS.

Bolt Biotherapeutics (NASDAQ:BOLT) last released its quarterly earnings data on Monday, March 24th. The company reported ($0.38) earnings per share for the quarter, meeting the consensus estimate of ($0.38). The firm had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.79 million. Bolt Biotherapeutics had a negative return on equity of 69.46% and a negative net margin of 665.56%.

Other equities analysts also recently issued reports about the stock. Stifel Nicolaus dropped their target price on shares of Bolt Biotherapeutics from $1.50 to $1.25 and set a “hold” rating for the company in a report on Tuesday. HC Wainwright reiterated a “neutral” rating on shares of Bolt Biotherapeutics in a research report on Tuesday. Five equities research analysts have rated the stock with a hold rating, According to data from MarketBeat.com, Bolt Biotherapeutics has an average rating of “Hold” and a consensus target price of $1.13.

Bolt Biotherapeutics Trading Down 3.3 %

Shares of BOLT stock opened at $0.43 on Friday. The stock has a market cap of $16.29 million, a P/E ratio of -0.25 and a beta of 0.94. The company has a quick ratio of 3.16, a current ratio of 3.16 and a debt-to-equity ratio of 0.21. Bolt Biotherapeutics has a fifty-two week low of $0.38 and a fifty-two week high of $1.56. The business has a fifty day simple moving average of $0.47 and a 200-day simple moving average of $0.55.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. FMR LLC grew its holdings in shares of Bolt Biotherapeutics by 33.2% during the third quarter. FMR LLC now owns 115,386 shares of the company’s stock worth $75,000 after buying an additional 28,773 shares in the last quarter. Citadel Advisors LLC acquired a new stake in Bolt Biotherapeutics during the fourth quarter worth approximately $42,000. Millennium Management LLC purchased a new stake in Bolt Biotherapeutics in the 4th quarter worth approximately $25,000. Squarepoint Ops LLC acquired a new position in Bolt Biotherapeutics in the 4th quarter valued at $26,000. Finally, Velan Capital Investment Management LP acquired a new position in Bolt Biotherapeutics in the 4th quarter valued at $27,000. 86.70% of the stock is currently owned by hedge funds and other institutional investors.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.